Skip to main content

Siemens Healthcare launch new 7 Tesla MRI research system

pharma courses

 

gpat

Siemens Healthcare planning to introduce the Magnetom Terra 7 Tesla MRI system to convert cutting-edge MRI research results into clinical application. This translation will allow user in less than ten minutes.  New 7 Tesla MRI system provides the whole range of cutting-edge 7 Tesla research functionalities, and is based on the latest software platform syngo MR E11, identical to Siemens’ latest flagship 3 Tesla MRI systems, to enable consistent usability and protocol exchange. It is the world’s first ultra-high field research system ready for future clinical use with planned CE and FDA authorization to market for selected neurological and musculoskeletal MR imaging applications.

[adsense:336x280:8701650588]

MAGNETOM Terra1 comes equipped with the latest ultra-high-field technological features, aiding you in obtaining excellent image quality to support your 7T MRI clinical and research endeavors.New actively shielded magnet is the lightest 7 Tesla whole body magnet in the world – 50 per cent lighter than previous actively shielded 7 Tesla magnet generations. This is the result of a multi-year engineering project at Siemens Magnet Technologies in Oxford, capitalizing on the long-term experience of the team in the design and manufacturing of state-of-the-art 3 Tesla magnets for clinical use. As a result, with Magnetom Terra, siting of a 7 Tesla MRI system becomes much easier and its location in a clinical environment becomes feasible. Combined with the Zero Helium boil-off technology, Magnetom Terra improves the lifecycle costs of ultra-high field MRI.

[adsense:468x15:2204050025]

MAGNETOM Terra’s improved workflow and Quiet Suite, help you improve patient and/or volunteer experience.This specially designed 7 Tesla technology makes this possible by offering up to eight channel parallel transmit technology for selective excitation and higher homogeneity in challenging body regions such as cardiac and abdominal.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>